281 related articles for article (PubMed ID: 36400660)
1. Relative effectiveness of a 2nd booster dose of COVID-19 mRNA vaccine up to four months post administration in individuals aged 80 years or more in Italy: A retrospective matched cohort study.
Fabiani M; Mateo-Urdiales A; Sacco C; Rota MC; Petrone D; Bressi M; Del Manso M; Siddu A; Proietti V; Battilomo S; Menniti-Ippolito F; Popoli P; Bella A; Riccardo F; Palamara AT; Rezza G; Brusaferro S; Pezzotti P;
Vaccine; 2023 Jan; 41(1):76-84. PubMed ID: 36400660
[TBL] [Abstract][Full Text] [Related]
2. Relative effectiveness of monovalent and bivalent mRNA boosters in preventing severe COVID-19 due to omicron BA.5 infection up to 4 months post-administration in people aged 60 years or older in Italy: a retrospective matched cohort study.
Mateo-Urdiales A; Sacco C; Fotakis EA; Del Manso M; Bella A; Riccardo F; Bressi M; Rota MC; Petrone D; Siddu A; Fedele G; Stefanelli P; Palamara AT; Brusaferro S; Rezza G; Pezzotti P; Fabiani M
Lancet Infect Dis; 2023 Dec; 23(12):1349-1359. PubMed ID: 37478877
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness against severe COVID-19 of a seasonal booster dose of bivalent (original/Omicron BA.4-5) mRNA vaccines in persons aged ≥60 years: Estimates over calendar time and by time since administration during prevalent circulation of different Omicron subvariants, Italy, 2022-2023.
Fabiani M; Mateo-Urdiales A; Sacco C; Fotakis EA; Battilomo S; Petrone D; Del Manso M; Bella A; Riccardo F; Stefanelli P; Palamara AT; Pezzotti P;
Vaccine; 2024 Jun; ():. PubMed ID: 38834428
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of the booster dose of inactivated COVID-19 vaccine against Omicron BA.5 infection: a matched cohort study of adult close contacts.
Zeng T; Lu Y; Zhao Y; Guo Z; Sun S; Teng Z; Tian M; Wang J; Li S; Fan X; Wang W; Cai Y; Liao G; Liang X; He D; Wang K; Zhao S
Respir Res; 2023 Oct; 24(1):246. PubMed ID: 37828565
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of Booster Doses of Monovalent mRNA COVID-19 Vaccine Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Children, Adolescents, and Adults During Omicron Subvariant BA.2/BA.2.12.1 and BA.4/BA.5 Predominant Periods.
Ciesla AA; Wiegand RE; Smith ZR; Britton A; Fleming-Dutra KE; Miller J; Accorsi EK; Verani JR; Shang N; Derado G; Pilishvili T; Link-Gelles R
Open Forum Infect Dis; 2023 May; 10(5):ofad187. PubMed ID: 37213428
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study.
Andersson NW; Thiesson EM; Baum U; Pihlström N; Starrfelt J; Faksová K; Poukka E; Meijerink H; Ljung R; Hviid A
BMJ; 2023 Jul; 382():e075286. PubMed ID: 37491022
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of mRNA vaccine boosters against infection with the SARS-CoV-2 omicron (B.1.1.529) variant in Spain: a nationwide cohort study.
Monge S; Rojas-Benedicto A; Olmedo C; Mazagatos C; José Sierra M; Limia A; Martín-Merino E; Larrauri A; Hernán MA;
Lancet Infect Dis; 2022 Sep; 22(9):1313-1320. PubMed ID: 35658998
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study.
Fabiani M; Puopolo M; Morciano C; Spuri M; Spila Alegiani S; Filia A; D'Ancona F; Del Manso M; Riccardo F; Tallon M; Proietti V; Sacco C; Massari M; Da Cas R; Mateo-Urdiales A; Siddu A; Battilomo S; Bella A; Palamara AT; Popoli P; Brusaferro S; Rezza G; Menniti Ippolito F; Pezzotti P;
BMJ; 2022 Feb; 376():e069052. PubMed ID: 35144968
[TBL] [Abstract][Full Text] [Related]
9. Relative vaccine effectiveness of mRNA COVID-19 boosters in people aged at least 75 years during the spring-summer (monovalent vaccine) and autumn-winter (bivalent vaccine) booster campaigns: a prospective test negative case-control study, United Kingdom, 2022.
Chatzilena A; Hyams C; Challen R; Marlow R; King J; Adegbite D; Kinney J; Clout M; Maskell N; Oliver J; Finn A; Danon L;
Euro Surveill; 2023 Nov; 28(48):. PubMed ID: 38037728
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of mRNA COVID-19 Vaccine Boosters Against Infection, Hospitalization, and Death: A Target Trial Emulation in the Omicron (B.1.1.529) Variant Era.
Ioannou GN; Bohnert ASB; O'Hare AM; Boyko EJ; Maciejewski ML; Smith VA; Bowling CB; Viglianti E; Iwashyna TJ; Hynes DM; Berry K;
Ann Intern Med; 2022 Dec; 175(12):1693-1706. PubMed ID: 36215715
[TBL] [Abstract][Full Text] [Related]
11. Relative Vaccine Effectiveness of a Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccine Booster Dose Against the Omicron Variant.
Butt AA; Talisa VB; Shaikh OS; Omer SB; Mayr FB
Clin Infect Dis; 2022 Dec; 75(12):2161-2168. PubMed ID: 35511586
[TBL] [Abstract][Full Text] [Related]
12. Transmission characteristics and inactivated vaccine effectiveness against transmission of the SARS-CoV-2 Omicron BA.2 variant in Shenzhen, China.
He X; Liao Y; Liang Y; Yu J; Gao W; Wan J; Liao Y; Su J; Zou X; Tang S
Front Immunol; 2023; 14():1290279. PubMed ID: 38259438
[TBL] [Abstract][Full Text] [Related]
13. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study.
Arbel R; Peretz A; Sergienko R; Friger M; Beckenstein T; Duskin-Bitan H; Yaron S; Hammerman A; Bilenko N; Netzer D
Lancet Infect Dis; 2023 Aug; 23(8):914-921. PubMed ID: 37062302
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of Messenger RNA-1273 Vaccine Booster Against Coronavirus Disease 2019 in Immunocompetent Adults.
Florea A; Sy LS; Qian L; Ackerson BK; Luo Y; Tubert JE; Lee GS; Ku JH; Bruxvoort KJ; Talarico CA; Qiu S; Tian Y; Tseng HF
Clin Infect Dis; 2023 Jan; 76(2):252-262. PubMed ID: 36134518
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection - Increasing Community Access to Testing Program, United States, September-November 2022.
Link-Gelles R; Ciesla AA; Fleming-Dutra KE; Smith ZR; Britton A; Wiegand RE; Miller JD; Accorsi EK; Schrag SJ; Verani JR; Shang N; Derado G; Pilishvili T
MMWR Morb Mortal Wkly Rep; 2022 Dec; 71(48):1526-1530. PubMed ID: 36454688
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of booster vaccination with inactivated COVID-19 vaccines against SARS-CoV-2 Omicron BA.2 infection in Guangdong, China: a cohort study.
He X; Zeng B; Wang Y; Pang Y; Zhang M; Hu T; Liang Y; Kang M; Tang S
Front Immunol; 2023; 14():1257360. PubMed ID: 37915583
[TBL] [Abstract][Full Text] [Related]
18. Inactivated SARS-CoV-2 Vaccine Booster Against Omicron Infection Among Quarantined Close Contacts.
Liu D; Feng S; Sha F; Liao Y; Xie X; Huang F; Kong D; Zhang Z; Chen Z; Chen N; Gao W; Feng T; Zhao Z; Li B; Li Y; Zhu F; Yang Z; Lv Q; Feng Z; Tang J
JAMA Netw Open; 2023 Oct; 6(10):e2339507. PubMed ID: 37878315
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of an mRNA vaccine booster dose against SARS-CoV-2 infection and severe COVID-19 in persons aged ≥60 years and other high-risk groups during predominant circulation of the delta variant in Italy, 19 July to 12 December 2021.
Fabiani M; Puopolo M; Filia A; Sacco C; Mateo-Urdiales A; Spila Alegiani S; Del Manso M; D'Ancona F; Vescio F; Bressi M; Petrone D; Spuri M; Rota MC; Massari M; Da Cas R; Morciano C; Stefanelli P; Bella A; Tallon M; Proietti V; Siddu A; Battilomo S; Palamara AT; Popoli P; Brusaferro S; Rezza G; Riccardo F; Menniti Ippolito F; Pezzotti P
Expert Rev Vaccines; 2022 Jul; 21(7):975-982. PubMed ID: 35389748
[TBL] [Abstract][Full Text] [Related]
20. Relative effectiveness of bivalent Original/Omicron BA.4-5 mRNA vaccine in preventing severe COVID-19 in persons 60 years and above during SARS-CoV-2 Omicron XBB.1.5 and other XBB sublineages circulation, Italy, April to June 2023.
Fabiani M; Mateo-Urdiales A; Sacco C; Rota MC; Fotakis EA; Petrone D; Del Manso M; Siddu A; Stefanelli P; Bella A; Riccardo F; Rezza G; Palamara AT; Brusaferro S; Pezzotti P;
Euro Surveill; 2023 Aug; 28(32):. PubMed ID: 37561053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
